Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.50 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.50 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.50 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.50 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.50 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.50 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.50 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.50 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.50 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.48 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.47 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.64 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14293022 | 0.98 | TDP1 (0.67) | KDM4ETDP1MAPTRECQLBLM | |
| SCHEMBL30516160 | 0.98 | TDP1 (0.67) | KDM4ETDP1MAPTRECQLBLM | |
| SCHEMBL278495 | 0.98 | TDP1 (0.67) | KDM4ETDP1MAPTRECQLBLM | |
| SCHEMBL22499940 | 0.82 | TDP1 (0.53) | KDM4ETDP1MAPTRECQLBLM | |
| Isopropylamine SCHEMBL10604489 | 0.82 | TDP1 (0.70) | KDM4ETDP1MAPTRECQLBLM | |
| Levonordefrin SCHEMBL363800 | 0.81 | KDM4E (1.00) | KDM4ETDP1MAPTRECQLBLM | |
| Hydrochloric Acid SCHEMBL22723284 | 0.81 | ADRB1 (0.50) | KDM4ETDP1MAPTRECQLBLM | |
| Hydrochloric Acid SCHEMBL20188109 | 0.81 | ADRB1 (0.50) | KDM4ETDP1MAPTRECQLBLM | |
| Hydrochloric Acid SCHEMBL29062371 | 0.81 | SHBG (0.51) | KDM4ETDP1MAPTRECQLBLM | |
| Hydrochloric Acid SCHEMBL29062369 | 0.81 | SHBG (0.51) | KDM4ETDP1MAPTRECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113788660-A | High-strength anti-crack concrete | 天元建设集团有限公司 | 2021-12-14 | — | — | CN | claimed |
| CN-113788660-B | High-strength anti-cracking concrete | 天元建设集团有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-114292621-A | High-low temperature adhesive based on bioengineering protein and preparation method thereof | 清华大学 | 2022-04-08 | — | — | CN | disclosed |
| CN-113788660-A | High-strength anti-crack concrete | 天元建设集团有限公司 | 2021-12-14 | — | — | CN | disclosed |
| CN-113227056-A | Systems and methods for high performance, low cost and easy to apply antimicrobial coatings of N-halamine-dopamine copolymers | 康奈尔大学 | 2021-08-06 | — | — | CN | disclosed |
| CN-112569403-A | Construction method of bioactive slow-release coating based on polydopamine/graphene oxide/collagen nano-film | 深圳市人民医院 | 2021-03-30 | — | — | CN | disclosed |
| CN-111098557-B | High-strength flame-retardant silicon core pipe and preparation method thereof | 安徽徽一通讯科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-111098557-A | High-strength flame-retardant silicon core pipe and preparation method thereof | 安徽徽一通讯科技有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-8298519-B2 | Hair treatment compositions incorporating hair substantive polymers | CONOPCO, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2319838-A1 | Therapeutic Molecules and Methods-1 | Cortical Pty Ltd (AU) | 2011-05-11 | — | — | EP | disclosed |
| EP-2056788-A1 | HAIR TREATMENT COMPOSITIONS INCORPORATING HAIR SUBSTANTIVE POLYMERS | Unilever PLC (GB) | 2009-05-13 | — | — | EP | disclosed |
| US-7393930-B2 | Modified protein adhesives and lignocellulosic composites made from the adhesives | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2008-07-01 | — | — | US | disclosed |
| WO-2008025671-A1 | HAIR TREATMENT COMPOSITIONS INCORPORATING HAIR SUBSTANTIVE POLYMERS | UNILEVER PLC (GB) | 2008-03-06 | — | — | WO | disclosed |
| US-20060156954-A1 | Modified protein adhesives and lignocellulosic composites made from the adhesives | STATE OF OR. ACTING BY & THROUGH THE OR. STATE BOARD OF HIGHER EDU. ON BEHALF OF OR. STATE UNIV. | 2006-07-20 | — | — | US | disclosed |
| US-20060154977-A1 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD, CORPORATION | 2006-07-13 | — | — | US | disclosed |
| US-7060798-B2 | Modified protein adhesives and lignocellulosic composites made from the adhesives | STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1511736-A4 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2006-06-07 | — | — | EP | disclosed |
| EP-1511736-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | Cortical Pty Ltd (AU) | 2005-03-09 | — | — | EP | disclosed |
| US-20040037906-A1 | Modified protein adhesives and lignocellulosic composites made from the adhesives | STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE | 2004-02-26 | — | — | US | disclosed |
| WO-2003104203-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154977-A1 | Therapeutic molecules and methods-1 | MIF, IL1B, IL1A | ADRB2 2626/4885ADRB1 1432/4885ADRA1A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.